Business Context and Reporting Period
The filing is Ambac Financial Group, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2015. The request metadata identifies Octave Specialty Group Inc., but the supplied filing identifies Ambac Financial Group, Inc. as the registrant.
Ambac operates through Financial Guarantee and Financial Services segments. The financial guarantee business is in runoff and cannot write new business because of deterioration in Ambac Assurance’s financial condition. Management states that there is substantial doubt about the Company’s ability to continue as a going concern; the financial statements nevertheless assume continued operations.
Financial Highlights
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Net premiums earned | $71.5 million, versus $64.8 million | $198.1 million, versus $212.4 million |
| Total revenues | $87.7 million, versus $155.3 million | $473.9 million, versus $321.8 million |
| Net investment income | $64.2 million, versus $83.6 million | $201.9 million, versus $234.5 million |
| Loss and loss expenses | $133.2 million benefit, versus $28.7 million benefit | $431.6 million benefit, versus $6.6 million expense |
| Goodwill impairment | $514.5 million | $514.5 million |
| Net income attributable to common shareholders | $(391.0) million, versus $82.5 million | $106.4 million, versus $30.5 million |
| Diluted earnings per share | $(8.66), versus $1.77 | $2.30, versus $0.65 |
| Operating earnings, non-GAAP | $170.5 million, versus $142.7 million | $684.2 million, versus $206.0 million |
Reported third-quarter results were dominated by the $514.5 million non-cash, non-tax-deductible goodwill impairment charge. The nine-month GAAP profit benefited substantially from positive loss-reserve development and fair-value movements, including variable interest entity and derivative effects.
- Cash flow from operating activities was $80.9 million for the nine months, compared with $258.4 million in the prior-year period.
- Investing cash flow was $(181.9) million, reflecting purchases of investments exceeding proceeds from sales and maturities.
- Financing cash flow was $54.2 million, including proceeds from a secured borrowing.
- Net cash flow was $(46.8) million; cash and cash equivalents ended at $27.1 million, compared with $43.3 million at September 30, 2014.
- Total assets were $24.27 billion, down from $25.16 billion at December 31, 2014.
- Total liabilities were $22.64 billion, down from $23.49 billion at December 31, 2014.
- Total stockholders’ equity was $1.63 billion, down from $1.67 billion at year-end 2014; Ambac Financial Group common stockholders’ equity was $1.36 billion.
- Long-term debt was $1.12 billion, excluding $12.79 billion of consolidated variable-interest-entity debt.
Material Changes Versus Prior Comparable Period
- Third-quarter net income changed to a $391.0 million loss from $82.5 million of income, primarily because of the goodwill impairment, larger derivative-product losses, losses on consolidated VIEs and lower investment income.
- Nine-month net income increased to $106.4 million from $30.5 million, primarily because of a $431.6 million loss-and-loss-expense benefit versus a $6.6 million expense in 2014, lower derivative-product losses and higher VIE income.
- Loss reserves and related expenses benefited from positive development in RMBS, student loans and domestic public finance, partly offset by adverse development in certain Ambac UK and public finance exposures.
- Net insured par outstanding declined to $119.0 billion from $144.7 billion at December 31, 2014, reflecting runoff, commutations, maturities and other reductions.
- The Financial Guarantee reporting unit’s goodwill was reduced from $514.5 million to zero following an interim impairment test driven by lower market capitalization, wider credit spreads and valuation changes.
- Ambac entered into a secured borrowing transaction in July 2015, receiving approximately $146.0 million of cash before expenses; carrying value of the related third-party debt was $137.0 million at September 30, 2015.
- The Company repurchased 577,500 warrants for $5.0 million during 2015. The remaining 4,461,637 warrants have an exercise price of $16.67 and expire April 30, 2023.
Outlook, Liquidity, Risks and Unusual Items
- Ambac’s corporate liquidity was approximately $149.2 million of cash and liquid investments at September 30, 2015, plus $93.2 million of less-liquid Ambac Assurance-insured RMBS and surplus notes.
- Ambac Assurance is highly unlikely to pay dividends to Ambac in the foreseeable future. Parent liquidity therefore depends primarily on existing cash and investments, expense-sharing arrangements and potential NOL-related payments.
- Ambac Assurance’s policyholder surplus was $350.6 million, above the $100.0 million minimum surplus amount required under arrangements with the Segregated Account. A decline below that threshold could create funding shortfalls and increase the risk of broader rehabilitation proceedings.
- The Segregated Account had $2.98 billion of Deferred Amounts and $449.4 million of unpaid accrued interest at September 30, 2015. Payments and the timing of such payments remain subject to the Rehabilitator and, where required, the Rehabilitation Court.
- Management is considering asset monetizations and a possible exchange or restructuring of surplus notes and Deferred Amounts, but no agreement had been reached as of the filing date.
- Ambac launched a gradual program in October 2015 to invest in residential real estate owned properties from insured transactions.
- Recorded RMBS subrogation recoveries were approximately $2.6 billion. The Company cautions that recoveries depend on litigation outcomes, sponsor creditworthiness, contractual interpretations and regulatory or rehabilitator actions.
- Management identified reasonably possible additional loss-reserve increases of approximately $121 million for certain RMBS exposures, $313 million for student loans, $1.247 billion for public finance and $451 million for other credits including Ambac UK. These are stress estimates, not forecasts.
- Ambac UK had a regulatory capital deficiency of approximately £323.9 million at September 30, 2015, although management stated that it remained able to meet obligations as they became due.
- Derivative and investment valuations remain sensitive to interest rates, credit spreads, foreign exchange rates and Ambac’s own credit valuation adjustment. All ratings-based collateral triggers for applicable derivatives had been activated.
- Pending litigation and regulatory matters generally lacked material accruals, but the Company stated that adverse outcomes could materially affect business, financial position, profitability or cash flows.
Important Facts for Investors to Verify
- Confirm the registrant identity: the supplied filing is for Ambac Financial Group, Inc., not Octave Specialty Group Inc.
- Assess the going-concern disclosure, parent liquidity, restricted dividend capacity and the timing of potential payments from Ambac Assurance.
- Evaluate the sustainability of earnings excluding the goodwill impairment and the significant reserve, VIE, derivative and credit-valuation adjustments.
- Review the assumptions supporting the $2.6 billion of RMBS subrogation recoveries and the potential additional loss scenarios.
- Monitor the Segregated Account rehabilitation proceedings, Deferred Amounts, surplus-note payments and any proposed debt or insurance-obligation exchange.
- Track Ambac Assurance’s policyholder surplus relative to the $100 million minimum and Ambac UK’s regulatory capital shortfall.
- Review exposure to Puerto Rico, RMBS, student loans, municipal credits, interest-rate derivatives and other below-investment-grade obligations.